Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0M1IN
|
|||
| Former ID |
DIB018002
|
|||
| Drug Name |
acelarin
|
|||
| Synonyms |
NUC-1031
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Biliary tract cancer [ICD-11: 2C17; ICD-10: C24.9] | Phase 3 | [1] | |
| Ovarian cancer [ICD-11: 2C73; ICD-10: C56] | Phase 2 | [2] | ||
| Alzheimer disease [ICD-11: 8A20; ICD-10: G30, G30.9; ICD-9: 331] | Phase 1 | [3] | ||
| Structure |
 |
Download2D MOL |
||
| Formula |
C25H27F2N4O8P
|
|||
| Canonical SMILES |
CC(C(=O)OCC1=CC=CC=C1)NP(=O)(OCC2C(C(C(O2)N3C=CC(=NC3=O)N)(F)F)O)OC4=CC=CC=C4
|
|||
| InChI |
1S/C25H27F2N4O8P/c1-16(22(33)36-14-17-8-4-2-5-9-17)30-40(35,39-18-10-6-3-7-11-18)37-15-19-21(32)25(26,27)23(38-19)31-13-12-20(28)29-24(31)34/h2-13,16,19,21,23,32H,14-15H2,1H3,(H,30,35)(H2,28,29,34)/t16-,19+,21+,23+,40?/m0/s1
|
|||
| InChIKey |
NHTKGYOMICWFQZ-KKQYNPQSSA-N
|
|||
| CAS Number |
CAS 840506-29-8
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | DNA synthesis (DNA synth) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04163900) Comparing NUC-1031 Plus Cisplatin to Gemcitabine Plus Cisplatin in Patients With Advanced Biliary Tract Cancer. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | Harnessing gemcitabine metabolism: a step towards personalized medicine for pancreatic cancer. Ther Adv Med Oncol. 2012 Nov;4(6):341-6. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.